Orion Portfolio Solutions LLC Has $28.80 Million Position in Johnson & Johnson (NYSE:JNJ)

Orion Portfolio Solutions LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.3% during the fourth quarter, HoldingsChannel reports. The firm owned 199,113 shares of the company’s stock after selling 2,675 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Johnson & Johnson were worth $28,796,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of JNJ. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the last quarter. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $35,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter worth $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JNJ. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Citigroup decreased their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Morgan Stanley cut their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Raymond James lowered their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Trading Up 0.9 %

Shares of NYSE JNJ opened at $163.22 on Friday. The company has a 50-day moving average of $158.35 and a two-hundred day moving average of $156.23. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $393.33 billion, a PE ratio of 24.54, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.